The Galleri Test Explained: Multi-Cancer Early Detection Cost, Who Should Consider It, and How to Order One
The Galleri® test is a single blood draw that screens for signals from more than 50 types of cancer simultaneously — most of which have no other recommended routine screening today. It currently costs $949 out of pocket for most Americans, requires a prescription from a licensed provider, and is not yet covered by Medicare or most commercial insurance. If a signal is detected, the test predicts where in the body the cancer may have originated, guiding your provider toward the right diagnostic follow-up.
What Is the Galleri Test and Is It Covered by Insurance?
Galleri, made by GRAIL, is a multi-cancer early detection (MCED) test that analyzes cell-free DNA (cfDNA) shed by tumors into your bloodstream. With one blood draw, it can identify a cancer signal and — when a signal is found — predict the Cancer Signal of Origin with greater than 90% accuracy, helping your provider decide where to look next.
GRAIL submitted its Premarket Approval (PMA) application to the FDA in January 2026. An FDA regulatory decision is anticipated before the end of 2026, which would make Galleri the first federally approved MCED test in the United States.
Current coverage status (September 2026):
| Payer Type | Coverage Status |
|---|---|
| Most commercial insurers | Not covered — self-pay at ~$949 retail |
| Medicare | Not yet covered; Congress voted to allow coverage starting 2028 |
| Curative Insurance | $0 copay for eligible plan members |
| Some employer self-funded plans | Select early adopters covering it |
Until broader coverage arrives, most patients pay the retail price directly through GRAIL’s ordering process. Telehealth providers can write the required prescription during a virtual visit.
What Does the Galleri Test Screen For?
Standard cancer screening programs — colonoscopy, mammogram, Pap smear, and low-dose CT for long-term smokers — collectively address only four to five cancer types. The Galleri test’s reach spans more than 50 cancer types, including many with no existing population-level screening program:
- Pancreatic cancer
- Ovarian cancer
- Liver and bile duct cancers
- Stomach and esophageal cancer
- Lung cancer (complementing low-dose CT for smokers)
- Multiple myeloma
- Head and neck cancers
- Thyroid, bladder, and kidney cancers
Critical context: A positive Galleri result means a cancer signal was detected in your blood — not that cancer is definitively present. A negative result does not guarantee you are cancer-free. Galleri is designed to work alongside standard screenings, not replace them.
What Did the 2026 Clinical Trials Show?
Two major datasets presented at the 2026 ASCO Annual Meeting offer the strongest real-world evidence to date on how Galleri performs.
NHS-Galleri Randomized Controlled Trial
The NHS-Galleri trial is the first and only randomized controlled trial of any MCED test. Conducted across England’s National Health Service over three years, it enrolled 142,250 participants aged 50 to 77. Adding the Galleri test to standard-of-care screening produced:
- A 4-fold increase in screen-detected cancers
- A 16% increase in Stage I–II (early, more treatable) cancer diagnoses
- A >20% reduction in Stage IV (advanced) diagnoses after the first year
- A 21% decrease in cancers first detected only after symptoms appeared — typically the most dangerous presentation
The trial did not meet its pre-specified primary statistical endpoint (a reduction in combined Stage III–IV diagnoses across 12 cancer types after three rounds). Researchers note the study may have needed a longer follow-up horizon; the direction of results was consistently favorable across secondary endpoints.
PATHFINDER 2 Study (35,000+ Participants)
GRAIL’s PATHFINDER 2 study enrolled more than 35,000 participants and demonstrated that Galleri substantially increased cancer detection with robust performance. The false positive rate — a test result that triggers unnecessary follow-up workup in a cancer-free patient — was among the lowest of any cancer screening test evaluated. This matters: unnecessary biopsies and imaging carry their own costs and risks.
These two datasets underpinned GRAIL’s FDA PMA filing and, pending agency review, could position Galleri as the first guideline-supported MCED test in the United States.
Who Should Consider Getting the Galleri Test?
The right candidate for Galleri depends on individual risk factors, existing screening history, and a clinical conversation with a provider. Based on the available evidence:
Profiles where Galleri may add meaningful value:
| Profile | Why It May Be Worth Considering |
|---|---|
| Age 50–77, average risk | The NHS trial population; broadest evidence base |
| Personal or family history of cancer | Higher baseline risk increases pretest probability of a true positive |
| Cancers that “run in the family” without a known gene (no BRCA/Lynch) | Galleri may detect a signal standard genetics cannot predict |
| Patients who want broader preventive surveillance | Complements colonoscopy, mammogram, lung CT, and PSA |
| Long-term smokers or former smokers | Elevated risk across multiple cancer types simultaneously |
Groups where evidence is less established:
- Under age 45: Cancer incidence is low in this group; a low pretest probability raises the relative likelihood that a positive is a false positive
- Active cancer diagnosis: Galleri is a screening test, not a monitoring tool for known disease
- Pregnant individuals: Cell-free DNA from placental tissue can interfere with interpretation
As of 2026, the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) have not issued formal endorsement guidelines for MCED tests. An FDA approval decision would likely accelerate guideline review by both bodies.
How Is the Galleri Test Ordered?
Galleri requires a prescription — you cannot self-order from a lab. Here is the typical process:
- Consult a licensed provider — a telehealth visit is sufficient; your provider reviews your risk factors and determines whether Galleri is clinically appropriate for you
- Blood draw at a Quest Diagnostics location — GRAIL processes samples through its lab partnership with Quest, which has more than 2,200 patient service centers nationwide; no at-home finger-stick option is available for this test
- Results in approximately two weeks — reported as either Negative (no cancer signal detected) or Positive (cancer signal found, with predicted origin site)
- Follow-up with your provider — a positive result initiates a diagnostic workup guided by the predicted origin, such as targeted imaging or referral to a specialist; the test result alone is never a cancer diagnosis
Omnia TeleHealth’s Galleri Cancer Screening service includes a provider consultation, prescription (if appropriate for your situation), and guidance on what your result means.
How Does Galleri Compare to Standard Cancer Screenings?
| Screening Method | Cancer Types Covered | Typical Frequency | Estimated Cost | Prescription Required? |
|---|---|---|---|---|
| Galleri (MCED blood test) | 50+ types | Annual | ~$949 | Yes |
| Colonoscopy | Colorectal | Every 10 yr (average risk) | $1,500–$3,000+ | Yes |
| Mammogram | Breast | Annual (age 40+) | $100–$250 | No (most states) |
| Low-dose CT (LDCT) | Lung | Annual (smokers 50–80) | $200–$600 | Yes |
| Pap smear + HPV co-test | Cervical | Every 3–5 yr | $50–$150 | Yes |
| PSA blood test | Prostate signal | Varies by guidelines | $40–$100 | Yes |
Galleri does not replace any of the above — it extends coverage into the large category of cancers that current programs miss entirely.
Frequently Asked Questions
What does a negative Galleri result mean?
A negative result means no cancer signal was detected at the time of testing. It does not guarantee you are cancer-free — the test has finite sensitivity and may not detect every cancer type, particularly very early or slow-growing tumors. Continue all age-appropriate standard screenings as recommended by your provider.
How accurate is the Galleri test?
When a cancer signal is detected, Galleri predicts the tissue of origin with greater than 90% accuracy, according to GRAIL’s published data. The false positive rate is low relative to other MCED tests evaluated. However, a positive result always requires follow-up diagnostic workup — imaging, biopsy, or specialist referral — to confirm or rule out cancer.
Does Medicare cover the Galleri test in 2026?
Not yet. Congress passed legislation allowing Medicare to cover multi-cancer early detection tests beginning in 2028. Until that coverage takes effect, Medicare beneficiaries generally pay the retail price (~$949) out of pocket.
Can I order the Galleri test through a telehealth provider?
Yes. A telehealth provider can evaluate your risk profile, write the required prescription, and help you interpret your results — all through a virtual visit. The blood draw itself must occur at a Quest Diagnostics patient service center; there is no at-home self-collection option for Galleri.
How often should I get the Galleri test?
The NHS-Galleri trial used annual testing. GRAIL currently recommends annual screening for eligible individuals. Your provider can help determine the right frequency based on your age, family history, and other risk factors.
Talk to a Provider About Whether Galleri Is Right for You
The Galleri test represents one of the most significant shifts in preventive medicine in years — the potential to catch cancers earlier, in people with no symptoms and no existing screening pathway. The 2026 ASCO data show real-world benefit, and an FDA decision before year-end could open the door to broader coverage and guideline adoption.
At Omnia TeleHealth, licensed providers can walk you through your personal risk profile, help you weigh the evidence, and write your prescription if Galleri is appropriate — all from a same-day virtual visit. Learn more about our Galleri Cancer Screening service or schedule a consultation today. Early detection works best when it starts early.